The University of Chicago Header Logo

Connection

Harvey M. Golomb to Carcinoma, Bronchogenic

Back to Details
This is a "connection" page, showing publications Harvey M. Golomb has written about Carcinoma, Bronchogenic.
Harvey M. Golomb
Connection Strength
0.401
Carcinoma, Bronchogenic
  1. Guided biopsies of abnormalities on nuclear bone scans. Technique and indications. J Thorac Cardiovasc Surg. 1983 Mar; 85(3):396-403.
    View in: PubMed
    Score: 0.057
  2. Metastatic non-oat-cell bronchogenic carcinoma. Therapy with cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP). JAMA. 1978 Dec 15; 240(25):2743-6.
    View in: PubMed
    Score: 0.043
  3. Combined modality therapy for stage IIIMO non-oat cell bronchogenic carcinoma. Cancer Treat Rep. 1978 Mar; 62(3):327-32.
    View in: PubMed
    Score: 0.040
  4. Clinicopathologic correlations demonstrating the failure of 67gallium scanning in determining response to radiotherapy. Chest. 1978 Mar; 73(3):356-9.
    View in: PubMed
    Score: 0.040
  5. Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP)--effective four-drug combination chemotherapy for metastatic non-oat cell bronchogenic carcinoma. Cancer Treat Rep. 1976 Sep; 60(9):1225-30.
    View in: PubMed
    Score: 0.036
  6. Pleural involvement in stage IIIM0 non-small-cell bronchogenic carcinoma. A need to differentiate subtypes. Am J Clin Oncol. 1986 Jun; 9(3):255-61.
    View in: PubMed
    Score: 0.018
  7. CAMP chemotherapy for metastatic non-oat cell bronchogenic carcinoma. A 7-year experience (1975-1981) with 160 patients. Cancer. 1985 Nov 15; 56(10):2385-90.
    View in: PubMed
    Score: 0.017
  8. Malignant superior vena cava obstruction reconsidered: the role of diagnostic surgical intervention. Ann Thorac Surg. 1985 Sep; 40(3):285-8.
    View in: PubMed
    Score: 0.017
  9. Trial of vindesine, etoposide, and cisplatin in patients with previously treated, advanced-stage, non-small cell bronchogenic carcinoma. Cancer Treat Rep. 1984 Feb; 68(2):413-5.
    View in: PubMed
    Score: 0.015
  10. The use of serum albumin for further classification of Stage III non-oat cell lung cancer and its therapeutic implications. Ann Thorac Surg. 1984 Feb; 37(2):115-22.
    View in: PubMed
    Score: 0.015
  11. Treatment of modified Stage II (T1 N1 M0, T2 N1 M0) non-small cell bronchogenic carcinoma. A combined modality approach. J Thorac Cardiovasc Surg. 1983 Aug; 86(2):180-5.
    View in: PubMed
    Score: 0.015
  12. Metastatic non-small cell bronchogenic carcinoma: a randomized trial of sequential vs combination chemotherapy. Eur J Cancer Clin Oncol. 1983 Jan; 19(1):33-8.
    View in: PubMed
    Score: 0.014
  13. Prognostic factors in patients with non-small cell bronchogenic carcinoma and brain metastases. Cancer. 1982 May 01; 49(9):1916-9.
    View in: PubMed
    Score: 0.013
  14. Bronchogenic carcinoma located in the aortic window. The importance of the primary lesion as a determinant of survival. J Thorac Cardiovasc Surg. 1982 Apr; 83(4):551-62.
    View in: PubMed
    Score: 0.013
  15. Prognostic significance of immunological tests in lung cancer. Clin Exp Immunol. 1981 Feb; 43(2):362-9.
    View in: PubMed
    Score: 0.012
  16. Clinical value of quantitative ventilation-perfusion lung scans in the surgical management of bronchogenic carcinoma. J Thorac Cardiovasc Surg. 1980 Oct; 80(4):535-43.
    View in: PubMed
    Score: 0.012
  17. Sequential staging in bronchogenic carcinoma. Chest. 1979 Dec; 76(6):653-7.
    View in: PubMed
    Score: 0.011
  18. The relationship between immune reactivity, serum cortisol, and stage of disease in patients with non-oat-cell bronchogenic carcinoma. Surgery. 1979 Jul; 86(1):130-7.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.